What is Solid tumors Phase 1 C-met Kinase Inhibitor MSC2156119J Clinical Trial?

Category: Others

false

NCT01014936 is an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.

Last updated:
There are no evaluations for Solid tumors Phase 1 C-met Kinase Inhibitor MSC2156119J Clinical Trial.